Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yu-Chang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Lignans, Biphenyl Compounds, NF-kappa B, Mouth Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Chang Bing Show Chwan Memorial Hospital.
Abstract (Originalsprache)
Oral cancer, particularly oral squamous cell carcinoma (OSCC), often exhibits resistance to standard treatments like surgery, chemotherapy, and radiation therapy (RT). Magnolol, a bioactive compound from the bark of Magnolia officinalis, is recognised for its anti‐inflammatory, antioxidant, antimicrobial, and antitumor properties. This study aims to explore magnolol's potential to enhance the therapeutic efficacy of RT in oral cancer models. Using MOC1‐bearing animals, we evaluated the combined effect of magnolol and RT. The results showed that magnolol significantly suppressed tumour growth, delayed progression, and reduced tumour weight compared to control groups. Immune profiling revealed that magnolol plus RT promoted positive immune regulation by increasing M1 macrophages, dendritic cells, and activated cytotoxic T cells, while suppressing negative regulators like myeloid‐derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Immunohistochemical analysis also demonstrated enhanced activation of apoptosis‐related pathways including the cleavage of caspase‐3, ‐8, and ‐9. Furthermore, the combination of magnolol and RT did not induce significant toxicity, as evidenced by stable body weight, normal tissue pathology, and normal liver and kidney function markers. Notably, the phosphorylation levels of EGFR and NF‐κB were significantly reduced in the magnolol plus RT group, similar to the effects seen with erlotinib plus RT. In conclusion, these findings highlight magnolol's ability to enhance the efficacy of RT in oral cancer by targeting the EGFR/NF‐κB axis, inducing apoptosis, and modulating immune responses, presenting a promising therapeutic strategy for OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
- Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan.
- Department of Life Sciences, National Central University, Taoyuan, Taiwan.
- Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan.
- Department of Nursing, Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
- Department of Radiation Oncology, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan.
ORCID-Profile: Yu-Chang Liu, Fei-Ting Hsu
Förderung
- National Science and Technology Council
- Chang Bing Show Chwan Memorial Hospital
Zitieren
APA
Liu, Y. C., Liao, C. Y., Hsu, F. T., Wu, H. J., Chen, K. T., Lee, P. H., & Hsueh, W. T. (2025). Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70699
Vancouver
Liu YC, Liao CY, Hsu FT, Wu HJ, Chen KT, Lee PH, et al. Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70699
BibTeX
@article{Liu2025,
author = {Liu, Yu-Chang and Liao, Chih-Ying and Hsu, Fei-Ting and Wu, Hsing-Ju and Chen, Kuan-Tin and Lee, Pei-Hsuan and Hsueh, Wei-Ting},
title = {Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF‐κB Pathway and Immune Modulation},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70699}
}
EUVIMED